Reversal, maintenance or progression: What happens to the liver after a virologic cure of hepatitis C?

Antiviral Research

Volumn 107, Issue 1, 2014, Pages 23-30

  Lee, Youngmin A ^a   Friedman, Scott L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Fibrosis regression; Hepatitis C; Liver fibrosis; Stellate cells; Sustained virological response

Indexed keywords

CARCINOGENESIS; DISEASE COURSE; EXPERIMENTAL FIBROSIS; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION; REVIEW; RODENT MODEL; SUSTAINED VIROLOGICAL RESPONSE; SYMPOSIUM; TREATMENT RESPONSE; BIOPSY; CARCINOMA, HEPATOCELLULAR; COMPLICATION; HEPATITIS C, CHRONIC; LIVER; LIVER NEOPLASMS; PATHOLOGY; VIRUS LOAD;

ANTIVIRUS AGENT;

ANTIVIRAL AGENTS; BIOPSY; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; VIRAL LOAD;

EID: 84899810657     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.03.012     Document Type: Review

References (113)

1. S. Aleman, N. Rahbin, and O. Weiland et al. A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis Clin. Infect. Dis. 57 2013 230 236
2. C. Aloman, S.L. Friedman, and M. Merad Dendritic cells in alcoholic liver injury and fibrosis Alcohol. Clin. Exp. Res. 35 2011 776 781
3. G.L. Armstrong, A. Wasley, and E.P. Simard et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 Ann. Intern. Med. 144 2006 705 714
4. S. Aytug, D. Reich, and L.E. Sapiro et al. Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes Hepatology 38 2003 1384 1392
5. A. Balagopal, D.L. Thomas, and C.L. Thio IL28B and the control of hepatitis C virus infection Gastroenterology 139 2010 1865 1876
6. L.A. Balart, M. Lisker-Melman, and F.M. Hamzeh et al. Peginterferon alpha-2a plus ribavirin in Latino and Non-Latino Whites with HCV genotype 1: histologic outcomes and tolerability from the LATINO study Am. J. Gastroenterol. 105 2010 2177 2185
7. Y. Benhamou, M. Bochet, and V. Di Martino et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group Hepatology 30 1999 1054 1058
8. D. Bernstein, L. Kleinman, and C.M. Barker et al. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients Hepatology 35 2002 704 708
9. P.Y. Bochud, S. Bibert, and Z. Kutalik et al. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes Hepatology 55 2012 384 394
10. R.E. Braks, N. Ganne-Carrie, and H. Fontaine et al. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin World J. Gastroenterol. 13 2007 5648 5653
11. R.S. Britton, and B.R. Bacon Hereditary hemochromatosis and alcohol: a fibrogenic cocktail Gastroenterology 122 2002 563 565
12. S. Bruno, T. Stroffolini, and M. Colombo et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study Hepatology 45 2007 579 587
13. A. Canbay, P. Taimr, and N. Torok et al. Apoptotic body engulfment by a human stellate cell line is profibrogenic Lab. Invest. 83 2003 655 663
14. A.C. Cardoso, R. Moucari, and C. Figueiredo-Mendes et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis J. Hepatol. 52 2010 652 657
15. C.J. Chu, S.D. Lee, and T.H. Hung et al. Insulin resistance is a major determinant of sustained virological response in genotype 1 chronic hepatitis C patients receiving peginterferon alpha-2b plus ribavirin Aliment. Pharmacol. Ther. 29 2009 46 54
16. R. D'Ambrosio, A. Aghemo, and M.G. Rumi et al. A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis Hepatology 56 2012 532 543
17. Y.P. de Jong, C.M. Rice, and A. Ploss New horizons for studying human hepatotropic infections J. Clin. Invest. 120 2010 650 653
18. M. Dorner, J.A. Horwitz, and B.M. Donovan et al. Completion of the entire hepatitis C virus life cycle in genetically humanized mice Nature 501 2013 237 241
19. A.M. Elsharkawy, F. Oakley, and D.A. Mann The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis Apoptosis 10 2005 927 939
20. G.T. Everson, J. Trotter, and L. Forman et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy Hepatology 42 2005 255 262
21. J.A. Fallowfield, M. Mizuno, and T.J. Kendall et al. Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis J. Immunol. 178 2007 5288 5295
22. N.D. Freedman, J.E. Everhart, and K.L. Lindsay et al. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C Hepatology 50 2009 1360 1369
23. S.L. Friedman Mechanisms of hepatic fibrosis and therapeutic implications Nat. Clin. Pract. Gastroenterol. Hepatol. 1 2 2004 98 105
24. S.L. Friedman Reversibility of hepatic fibrosis and cirrhosis - is it all hype? Nat. Clin. Pract. Gastroenterol. Hepatol. 4 2 2007 236 237
25. S.L. Friedman Mechanisms of hepatic fibrogenesis Gastroenterology 134 2008 1655 1669
26. S.L. Friedman Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver Physiol. Rev. 88 2008 125 172
27. S.L. Friedman Fibrogenic cell reversion underlies fibrosis regression in liver Proc. Natl. Acad. Sci. USA 109 2012 9230 9231
28. S.L. Friedman, D. Sheppard, and J.S. Duffield et al. Therapy for fibrotic diseases: nearing the starting line Sci. Transl. Med. 5 2013 167sr1
29. B.H. Fu, Z.Z. Wu, and J. Qin Effects of integrin alpha6beta1 on migration of hepatocellular carcinoma cells Mol. Biol. Rep. 38 2011 3271 3276
30. S.L. George, B.R. Bacon, E.M. Brunt, K.L. Mihindukulasuriya, J. Hoffmann, and A.M. Di Bisceglie Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients Hepatology 49 3 2009 729 738
31. M.G. Ghany, D.B. Strader, and D.L. Thomas et al. Diagnosis, management, and treatment of hepatitis C: an update Hepatology 49 2009 1335 1374
32. D. Hashimoto, J. Miller, and M. Merad Dendritic cell and macrophage heterogeneity in vivo Immunity 35 2011 323 335
33. M. Hirakawa, K. Ikeda, and Y. Arase et al. Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients Intern. Med. 47 2008 1637 1643
34. Y. Hoshida, A. Villanueva, and M. Kobayashi et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma N. Engl. J. Med. 359 2008 1995 2004
35. H. Huang, M.L. Shiffman, and R.C. Cheung et al. Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C Gastroenterology 130 2006 1679 1687
36. H. Huang, M.L. Shiffman, and S. Friedman et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C Hepatology 46 2007 297 306
37. J.M. Hui, A. Sud, and G.C. Farrell et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected] Gastroenterology 125 2003 1695 1704
38. H.A. Innes, S.J. Hutchinson, and S. Allen et al. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care Hepatology 54 2011 1547 1558
39. J.P. Iredale, R.C. Benyon, and J. Pickering et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors J. Clin. Invest. 102 1998 538 549
40. R. Issa, X. Zhou, and N. Trim et al. Mutation in collagen-1 that confers resistance to the action of collagenase results in failure of recovery from CCl4-induced liver fibrosis, persistence of activated hepatic stellate cells, and diminished hepatocyte regeneration FASEB J. 17 2003 47 49
41. R. Issa, X. Zhou, and C.M. Constandinou et al. Spontaneous recovery from micronodular cirrhosis: evidence for incomplete resolution associated with matrix cross-linking Gastroenterology 126 2004 1795 1808
42. J. Jiao, D. Sastre, and M.I. Fiel et al. Dendritic cell regulation of carbon tetrachloride-induced murine liver fibrosis regression Hepatology 55 2012 244 255
43. A.A. John-Baptiste, G. Tomlinson, and P.C. Hsu et al. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C Am. J. Gastroenterol. 104 2009 2439 2448
44. K.R. Karlmark, R. Weiskirchen, and H.W. Zimmermann et al. Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis Hepatology 50 2009 261 274
45. T. Kisseleva, M. Cong, and Y. Paik et al. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis Proc. Natl. Acad. Sci. USA 109 2012 9448 9453
46. V. Krizhanovsky, M. Yon, and R.A. Dickins et al. Senescence of activated stellate cells limits liver fibrosis Cell 134 2008 657 667
47. H. Lerat, M. Higgs, and J.M. Pawlotsky Animal models in the study of hepatitis C virus-associated liver pathologies Expert Rev. Gastroenterol. Hepatol. 5 2011 341 352
48. K.R. Levental, H. Yu, and L. Kass et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling Cell 139 2009 891 906
49. E. Liaskou, D.V. Wilson, and Y.H. Oo Innate immune cells in liver inflammation Mediators Inflamm. 2012 2012 949157
50. A. Lin, A. Thadareddy, and M.J. Goldstein et al. Immune suppression leading to hepatitis C virus re-emergence after sustained virological response J. Med. Virol. 80 2008 1720 1722
51. T. Luedde, and R.F. Schwabe NF-kappaB in the liver - linking injury, fibrosis and hepatocellular carcinoma Nat. Rev. Gastroenterol. Hepatol. 8 2011 108 118
52. V. Mallet, H. Gilgenkrantz, J. Serpaggi, V. Verkarre, A. Vallet-Pichard, H. Fontaine, and S. Pol Brief communication: The relationship of regression of cirrhosis to outcome in chronic hepatitis C Ann. Intern. Med. 149 6 2008 399 403
53. M.P. Manns, J.G. McHutchison, S.C. Gordon, V.K. Rustgi, M. Shiffman, R. Reindollar, Z.D. Goodman, K. Koury, M. Ling, and J.K. Albrecht Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial Lancet 358 9286 2001 958 965
54. M.P. Manns, P.J. Pockros, and G. Norkrans et al. Long-term clearance of hepatitis C virus following interferon alpha-2b or peginterferon alpha-2b, alone or in combination with ribavirin J. Viral Hepat. 20 2013 524 529
55. P. Manousou, A.P. Dhillon, and G. Isgro et al. Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation Liver Transpl. 17 2011 178 188
56. P. Marcellin, N. Boyer, A. Gervais, M. Martinot, M. Pouteau, C. Castelnau, A. Kilani, J. Areias, A. Auperin, J.P. Benhamou, C. Degott, and S. Erlinger Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy Ann. Intern. Med. 127 10 1997 875 881
57. M. Martinot-Peignoux, C. Stern, and S. Maylin et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin Hepatology 51 2010 1122 1126
58. S. Maylin, M. Martinot-Peignoux, and R. Moucari et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C Gastroenterology 135 2008 821 829
59. S.H. Mehta, F.L. Brancati, and M.S. Sulkowski et al. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States Ann. Intern. Med. 133 2000 592 599
60. S.H. Mehta, A. Cox, and D.R. Hoover et al. Protection against persistence of hepatitis C Lancet 359 2002 1478 1483
61. J.A. Mengshol, L. Golden-Mason, and H.R. Rosen Mechanisms of disease: HCV-induced liver injury Nat. Clin. Pract. Gastroenterol. Hepatol. 4 2007 622 634
62. R.L. Morgan, B. Baack, and B.D. Smith et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies Ann. Intern. Med. 158 2013 329 337
63. R. Moucari, T. Asselah, and D. Cazals-Hatem et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis Gastroenterology 134 2008 416 423
64. A. Muzzi, G. Leandro, and L. Rubbia-Brandt et al. Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients J. Hepatol. 42 2005 41 46
65. B. Nalpas, R. Lavialle-Meziani, and S. Plancoulaine et al. Interferon gamma receptor 2 gene variants are associated with liver fibrosis in patients with chronic hepatitis C infection Gut 59 2010 1120 1126
66. F. Negro Steatosis and insulin resistance in response to treatment of chronic hepatitis C J. Viral Hepat. 19 Suppl. 1 2012 42 47
67. K. Ohata, K. Hamasaki, and K. Toriyama et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection Cancer 97 2003 3036 3043
68. E. Patin, Z. Kutalik, and J. Guergnon et al. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection Gastroenterology 143 2012 1244 1252 e1
69. B.L. Pearlman, and N. Traub Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more Clin. Infect. Dis. 52 2011 889 900
70. A. Pellicoro, R.L. Aucott, and P. Ramachandran et al. Elastin accumulation is regulated at the level of degradation by macrophage metalloelastase (MMP-12) during experimental liver fibrosis Hepatology 55 2012 1965 1975
71. A. Pellicoro, P. Ramachandran, and J.P. Iredale Reversibility of liver fibrosis Fibrogenesis Tissue Repair 5 Suppl. 1 2012 S26
72. S. Petta, C. Camma, and V. Di Marco et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection Am. J. Gastroenterol. 103 2008 1136 1144
73. H. Poustchi, F. Negro, and J. Hui et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3 J. Hepatol. 48 2008 28 34
74. T. Poynard, P. Bedossa, and M. Chevallier et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group N. Engl. J. Med. 332 1995 1457 1462
75. T. Poynard, J. McHutchison, and M. Manns et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C Gastroenterology 122 5 2002 1303 1313
76. T. Poynard, V. de Ledinghen, and J.P. Zarski et al. Performances of Elasto-FibroTest((R)), a combination between FibroTest((R)) and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C Clin. Res. Hepatol. Gastroenterol. 36 2012 455 463
77. T. Poynard, J. Moussalli, and M. Munteanu et al. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C J. Hepatol. 59 2013 675 683
78. P. Pradat, H.L. Tillmann, and S. Sauleda et al. Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications J. Viral Hepat. 14 2007 556 563
79. P. Ramachandran, A. Pellicoro, and M.A. Vernon et al. Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis Proc. Natl. Acad. Sci. USA 109 2012 E3186 E3195
80. V. Ramakrishnaiah, C. Thumann, and I. Fofana et al. Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells Proc. Natl. Acad. Sci. USA 110 2013 13109 13113
81. C. Ripoll, R. Groszmann, and G. Garcia-Tsao et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis Gastroenterology 133 2007 481 488
82. S. Roberts, A. Gordon, and C. McLean et al. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis Clin. Gastroenterol. Hepatol. 5 2007 932 937
83. M. Romero-Gomez, M. Del Mar Viloria, and R.J. Andrade Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients Gastroenterology 128 2005 636 641
84. D. Schuppan, M. Ruehl, and R. Somasundaram et al. Matrix as a modulator of hepatic fibrogenesis Semin. Liver Dis. 21 2001 351 372
85. D. Schuppan, A. Krebs, and M. Bauer et al. Hepatitis C and liver fibrosis Cell Death Differ. 10 Suppl. 1 2003 S59 S67
86. H.K. Seitz, and F. Stickel Risk factors and mechanisms of hepatocarcinogenesis with special emphasis on alcohol and oxidative stress Biol. Chem. 387 2006 349 360
87. Y. Shiratori, F. Imazeki, M. Moriyama, M. Yano, Y. Arakawa, O. Yokosuka, T. Kuroki, S. Nishiguchi, M. Sata, G. Yamada, S. Fujiyama, H. Yoshida, and M. Omata Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy Ann. Intern. Med. 132 7 2000 517 524
88. A. Shlomai, Y.P. de Jong, and C.M. Rice Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma Semin. Cancer Biol 2014 10.1016/j.semcancer.2014.01.004 [Epub ahead of print]
89. M.W. Smith, K.A. Walters, and M.J. Korth et al. Gene expression patterns that correlate with hepatitis C and early progression to fibrosis in liver transplant recipients Gastroenterology 130 2006 179 187
90. F. Tacke, and H.W. Zimmermann Macrophage heterogeneity in liver injury and fibrosis J. Hepatol. 60 5 2014 1090 1096 10.1016/j.jhep.2013.12.025
91. A. Tanaka, S. Uegaki, and H. Kurihara et al. Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C World J. Gastroenterol. 13 2007 5180 5187
92. H. Tang, and H. Grise Cellular and molecular biology of HCV infection and hepatitis Clin. Sci. (Lond.) 117 2009 49 65
93. R. Teixeira, L.A. Marcos, and S.L. Friedman Immunopathogenesis of hepatitis C virus infection and hepatic fibrosis: new insights into antifibrotic therapy in chronic hepatitis C Hepatol. Res. 37 2007 579 595
94. D.L. Thomas Global control of hepatitis C: where challenge meets opportunity Nat. Med. 19 2013 850 858
95. D.L. Thomas, and L.B. Seeff Natural history of hepatitis C Clin. Liver Dis. 9 2005 383 398 vi
96. K. Thomopoulos, N.C. Giannakoulas, and A.C. Tsamandas et al. Recurrence of HCV infection in a sustained responder after chemotherapy for non-Hodgkin's lymphoma: successful retreatment Am. J. Med. Sci. 336 2008 73 76
97. F. Toccaceli, V. Laghi, L. Capurso, M. Koch, S. Sereno, and M. Scuderi Long-term liver histology improvement in patients with chronic hepatitis C and sustained response to interferon J. Viral. Hepat. 10 2 2003 126 133
98. E. Trepo, P. Pradat, and A. Potthoff et al. Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C Hepatology 54 2011 60 69
99. J.S. Troeger, I. Mederacke, and G.Y. Gwak et al. Deactivation of hepatic stellate cells during liver fibrosis resolution in mice Gastroenterology 143 4 2012 1073 1083 e22
100. L. Valenti, M. Rumi, and E. Galmozzi et al. Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C Hepatology 53 2011 791 799
101. M. Valko, D. Leibfritz, and J. Moncol et al. Free radicals and antioxidants in normal physiological functions and human disease Int. J. Biochem. Cell Biol. 39 2007 44 84
102. A.J. van der Meer, B.J. Veldt, and J.J. Feld et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis JAMA 308 2012 2584 2593
103. B.J. Veldt, E.J. Heathcote, and H. Wedemeyer et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis Ann. Intern. Med. 147 2007 677 684
104. I.R. Wanless, E. Nakashima, and M. Sherman Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis Arch. Pathol. Lab. Med. 124 2000 1599 1607
105. M.L. Washburn, M.T. Bility, and L. Zhang et al. A humanized mouse model to study hepatitis C virus infection, immune response, and liver disease Gastroenterology 140 2011 1334 1344
106. R.G. Wells The role of matrix stiffness in regulating cell behavior Hepatology 47 4 2008 1394 1400
107. T. Yamashita, M. Honda, and S. Kaneko Molecular mechanisms of hepatocarcinogenesis in chronic hepatitis C virus infection J. Gastroenterol. Hepatol. 26 2011 960 964
108. N. Yamashita, A. Ohho, and A. Yamasaki et al. Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes J. Gastroenterol. 2013 [Epub ahead of print]
109. H. Yoshida, Y. Shiratori, and M. Moriyama et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy Ann. Intern. Med. 131 1999 174 181
110. H. Yoshiji, S. Kuriyama, and Y. Miyamoto et al. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model Hepatology 32 2000 1248 1254
111. S. Zeuzem, E.J. Heathcote, and M.L. Shiffman et al. Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C J. Hepatol. 39 2003 106 111
112. D.Y. Zhang, and S.L. Friedman Fibrosis-dependent mechanisms of hepatocarcinogenesis Hepatology 56 2012 769 775
113. H. Zhang, I. Ozaki, and T. Mizuta et al. Beta 1-integrin protects hepatoma cells from chemotherapy induced apoptosis via a mitogen-activated protein kinase dependent pathway Cancer 95 2002 896 906